Isoflurane attenuates murine lupus nephritis by inhibiting NLRP3 inflammasome activation

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 10, 2015, Pages 17730-17738

  Yuan, Yi ^a,b   Liu, Zhangsuo ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Isoflurane; Lupus nephritis; NLRP3 inflammasome

Indexed keywords

AUTOANTIBODY; CASPASE; CASPASE 1P20; CRYOPYRIN; DOUBLE STRANDED DNA; INTERLEUKIN 17; INTERLEUKIN 1BETA; ISOFLURANE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNE COMPLEX DEPOSITION; IMMUNE COMPLEX DISEASE; IMMUNOHISTOCHEMISTRY; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE ACTIVATION; MORTALITY; MOUSE; NONHUMAN; PROTEINURIA; REGULATORY T LYMPHOCYTE; SPLEEN CELL; SURVIVAL RATE; TH17 CELL; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING;

EID: 84949655996     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. [1] Nowling TK and Gilkeson GS. Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther 2011; 13: 250.
2. [2] Davidson A and Aranow C. Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol 2006; 18: 468-475.
3. [3] Faurschou M, Dreyer L, Kamper AL, Starklint H and Jacobsen S. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken) 2010; 62: 873-880.
4. [4] Grande JP. Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring. Lupus 1998; 7: 604-610.
5. [5] Wen H, Ting JP and O’Neill LA. A role for the NLRP3 inflammasome in metabolic diseases–did Warburg miss inflammation? Nat Immunol 2012; 13: 352-357.
6. [6] Strowig T, Henao-Mejia J, Elinav E and Flavell R. Inflammasomes in health and disease. Nature 2012; 481: 278-286.
7. [7] Schroder K and Tschopp J. The Inflammasomes. Cell 2010; 140: 821-832.
8. [8] Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ and Golenbock DT. The NALP3 inflammasome is involved in the innate immune response to amyloidbeta. Nat Immunol 2008; 9: 857-865.
9. [9] Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT and Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008; 320: 674-677.
10. [10] Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V and Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-1361.
11. [11] Li XM, Zhou MT, Wang XM, Ji MH, Zhou ZQ and Yang JJ. Resveratrol pretreatment attenuates the isoflurane-induced cognitive impairment through its anti-inflammation and -apoptosis actions in aged mice. J Mol Neurosci 2014; 52: 286-293.
12. [12] Mu J, Xie K, Hou L, Peng D, Shang L, Ji G, Li J, Lu Y and Xiong L. Subanesthetic dose of isoflurane protects against zymosan-induced generalized inflammation and its associated acute lung injury in mice. Shock 2010; 34: 183-189.
13. [13] Li JT, Wang H, Li W, Wang LF, Hou LC, Mu JL, Liu X, Chen HJ, Xie KL, Li NL and Gao CF. Anesthetic isoflurane posttreatment attenuates experimental lung injury by inhibiting inflammation and apoptosis. Mediators Inflamm 2013; 2013: 108928.
14. [14] Wang H, Fan J, Li NL, Li JT, Yuan SF, Yi J, Wang L, Chen JH, Lv YG, Yao Q, Wang T, Wang YC and Ling R. A subanesthetic dose of isoflurane during postconditioning ameliorates zymosan-induced neutrophil inflammation lung injury and mortality in mice. Mediators Inflamm 2013; 2013: 479628.
15. [15] Jiang C, Foley J, Clayton N, Kissling G, Jokinen M, Herbert R and Diaz M. Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice. J Immunol 2007; 178: 7422-7431.
16. [16] Muraoka M, Hasegawa H, Kohno M, Inoue A, Miyazaki T, Terada M, Nose M and Yasukawa M. IK cytokine ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum 2006; 54: 3591-3600.
17. [17] Zhang L, Yang N, Wang S, Huang B, Li F, Tan H, Liang Y, Chen M, Li Y and Yu X. Adenosine 2A receptor is protective against renal injury in MRL/lpr mice. Lupus 2011; 20: 667-677.
18. [18] Schwartz N, Goilav B and Putterman C. The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol 2014; 26: 502-509.
19. [19] Michaelson JS, Wisniacki N, Burkly LC and Putterman C. Role of TWEAK in lupus nephritis: a bench-to-bedside review. J Autoimmun 2012; 39: 130-142.
20. [20] Zhao J, Zhang H, Huang Y, Wang H, Wang S, Zhao C, Liang Y and Yang N. Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-kB activation. Int Immunopharmacol 2013; 17: 116-122.
21. [21] Arbuckle MR, McClain MT, Rubertone MV, Scofi eld RH, Dennis GJ, James JA and Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533.
22. [22] Fenton KA and Rekvig OP. A central role of nucleosomes in lupus nephritis. Ann N Y Acad Sci 2007; 1108: 104-113.
23. [23] Rovin BH and Parikh SV. Lupus nephritis: the evolving role of novel therapeutics. Am J Kidney Dis 2014; 63: 677-690.
24. [24] Kulkarni O, Pawar RD, Purschke W, Eulberg D, Selve N, Buchner K, Ninichuk V, Segerer S and Vielhauer V. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas) lpr mice. J Am Soc Nephrol 2007; 18: 2350-2358.
25. [25] Zhang JL, Sun DJ, Hou CM, Wei YL, Li XY, Yu ZY, Feng JN, Shen BF, Li Y and Xiao H. CD3 mAb treatment ameliorated the severity of the cGVHD-induced lupus nephritis in mice by up-regulation of Foxp3+ regulatory T cells in the target tissue: kidney. Transpl Immunol 2010; 24: 17-25.
26. [26] Pisitkun P, Ha HL, Wang H, Claudio E, Tivy CC, Zhou H, Mayadas TN, Illei GG and Siebenlist U. Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 2012; 37: 1104-1115.
27. [27] Kyttaris VC, Zhang Z, Kuchroo VK, Oukka M and Tsokos GC. IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J Immunol 2010; 184: 4605-4509.
28. [28] Ouyang W, Kolls JK and Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28: 454-467.
29. [29] Apostolidis SA, Crispin JC and Tsokos GC. IL-17-producing T cells in lupus nephritis. Lupus 2011; 20: 120-124.
30. [30] Hu Q, Yang C, Wang Q, Zeng H and Qin W. Demethylzeylasteral (T-96) Treatment Ame-liorates Mice Lupus Nephritis Accompanied by Inhibiting Activation of NF-κB Pathway. PLoS One 2015; 10: e0133724.
31. [31] Zhao J, Wang H, Dai C, Wang H, Zhang H, Huang Y, Wang S, Gaskin F, Yang N and Fu SM. P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/caspase 1 pathway. Arthritis Rheum 2013; 65: 3176-3185.
32. [32] Tsai PY, Ka SM, Chang JM, Chen HC, Shui HA, Li CY, Hua KF, Chang WL, Huang JJ, Yang SS and Chen A. Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic Biol Med 2011; 51: 744-754.
33. [33] Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, Li Y, Clark SA, Tschopp J and Trpkov K. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 2010; 21: 1732-1744.
34. [34] Kahlenberg JM, Thacker SG, Berthier CC, Cohen CD, Kretzler M and Kaplan MJ. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol 2011; 187: 6143-6156.
35. [35] Eggleton P, Harries LW, Alberigo G, Wordsworth P, Viner N, Haigh R, Donnelly S, Jones HW and Chikanza IC. Changes in apoptotic gene expression in lymphocytes from rheumatoid arthritis and systemic lupus erythematosus patients compared with healthy lymphocytes. J Clin Immunol 2010; 30: 649-658.
36. [36] Saleh M. The machinery of Nod-like receptors: refining the paths to immunity and cell death. Immunol Rev 2011; 243: 235-246.
37. [37] Natarajan R, Salloum FN, Fisher BJ, Kukreja RC and Fowler AA 3rd. Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ Res 2006; 98: 133-140.